MESO · Mesoblast Limited

Mesoblast's Exhibit 99.1 press release highlights robust first-year performance for Ryoncil, its pioneering FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in pediatric patients aged 2 months and older. Net sales of US$30.3 million for the March 2026 quarter reflect strong uptake in February and March, countering typical January holiday seasonality, with cumulative revenue since launch nearing US$100 million. This revenue trajectory bolsters the company's balance sheet, enabling investment in label expansions for adult SR-aGvHD and biologic-resistant inflammatory bowel disease, alongside late-stage programs like rexlemestrocel-L for heart failure and chronic low back pain. CEO Dr. Silviu Itescu described the revenue as 'impressive,' signaling confidence in sustained growth. The timing aligns with Mesoblast's inaugural R&D Day on April 8, 2026, where leadership and key opinion leaders will detail commercialization strategies and pipeline advancements. Note that figures are preliminary, pending full financial close and audit, underscoring the need for investors to monitor final results. Ryoncil's status as the only FDA-approved therapy for children under 12 with this indication positions it uniquely in the inflammatory diseases market, supported by extensive IP protection through 2044 and industrial-scale manufacturing capabilities.